Iopidine

Apraclonidine, the active ingredient in Iopidine, is a Alpha-2 adrenergic agonist presented as a 0.5% w/v ophthalmic solution for ocular use. It lowers intra‑ocular pressure in patients with ocular hypertension, open‑angle glaucoma, and after ocular surgery.

GNH USA supplies Iopidine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Iopidine is an ocular antihypertensive that reduces intra‑ocular pressure in several eye conditions.

- Ocular hypertension: lowers pressure to prevent progression to glaucoma. - Open-angle glaucoma: reduces intra‑ocular pressure to preserve optic nerve function. - Post‑operative IOP elevation: helps control pressure after ocular surgery, aiding recovery.

Common Side Effects: - Ocular burning or stinging sensation. - Transient eye redness (hyperemia). - Itching or mild irritation of the ocular surface. - Blurred vision shortly after instillation. - Dry eye sensation. - Mild headache.

Serious or Rare Side Effects: - Allergic reactions such as angioedema or severe dermatitis. - Significant hypotension or bradycardia from systemic absorption. - Acute ocular inflammation or uveitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Persistent visual disturbances. - Severe ocular pain requiring urgent evaluation.

Before using Iopidine, consider the following precautions: - Hypersensitivity: avoid if the patient is allergic to apraclonidine or any excipient. - Cardiovascular disease: monitor patients with low blood pressure or heart block for systemic effects. - Narrow-angle glaucoma: use with caution as it may precipitate angle closure. - Contact lens wear: advise patients to remove lenses during treatment to reduce irritation. - Concomitant ocular medications: assess for additive IOP‑lowering effects. - Store at room temperature: keep in the original container, protect from light and moisture.

Apraclonidine may interact with other agents as follows.

Major Interactions (Avoid): - Co‑administration with other ocular alpha‑2 agonists (e.g., brimonidine) may cause excessive IOP reduction and systemic hypotension. - Use with systemic adrenergic antagonists may amplify cardiovascular effects.

Moderate Interactions (Monitor Closely): - Concurrent use of topical NSAIDs may increase ocular irritation. - Beta‑blocker eye drops can produce additive IOP‑lowering; monitor pressure. - Systemic antihypertensives may enhance hypotensive response. - Certain contact lens solutions may affect drug stability; verify compatibility.